42 results about "Mucus layer" patented technology

The invention belongs to pharmaceutical preparations containing protein materials. It is an oral preparation of intestinal trefoil factor, which is characterized in that it contains intestinal trefoil factor as a pharmacodynamic active component, and also contains intestinal trefoil factor activator and intestinal trefoil factor protective agent. It is clinically used for the treatment of gastrointestinal ischemia-hypoxic injury, such as peptic ulcer, radiation enteritis, chronic gastritis, enteritis and other diseases caused by various reasons, and can rapidly promote the proliferation of gastrointestinal epithelial cells, Stabilizes the gastrointestinal mucus layer, does not interfere with glucose metabolism and promote gluconeogenesis, and has no side effects of promoting the expression of bacterial drug resistance genes and promoting the growth of tumor cells.

The invention relates to a reduction-responsive targeting polymer micelle for mucus penetration and a preparation method thereof. Combining PLGA and PEG through reduction-responsive disulfide bonds to form an amphiphilic polymer conjugate, and post-assembly to form reduction-responsive micelles to achieve good mucus permeability, reduction-responsive bond breaking performance and targeting cell-mediated The performance of endocytosis, and the effective particle size is 70-110nm, and the particle size is more uniform; due to the coating of PEG, the surface of micelles is neutral, and the cytotoxicity is low, and it can penetrate into the bottom cell layer in the mucus layer and reach the bottom cells After injection of glutathione solution, the reduction-responsive disulfide bond breaks, the PEG protection is removed, and the coated targeted folic acid is exposed, which specifically binds to the folic acid receptor overexpressed on the cell membrane surface of the lesion cell, and is mediated by folic acid Receptor-mediated endocytosis improves the efficiency of nanocarriers entering cells, allowing more carriers to enter cells for slow and controlled release of drugs, achieving better therapeutic effects.

The invention discloses a method for efficiently extracting internal mucus layers of arabidopsis thaliana, belonging to the field of polysaccharide extraction. In the method disclosed by the invention, the internal mucus layers are extracted using ultrasonic. The method is economical and simplifies operation, wherein the extraction solution is water, and a large quantity of seed coat mucus layers can be obtained without desalting treatment; and in extraction using an acid-alkali-salt process, residual salt needs to be removed. The time is saved, wherein the extraction time using a vibration process and an alkali salt process is generally 1-2h and desalting is also needed in later period, and the method disclosed by the invention can finish the extraction within 20s. The extraction efficiency is high, wherein a large quantity of residual mucus layers are shown after the seed extracted by the vibration process and acid-alkali-salt process is dyed by ruthenium red; and after the extraction using the method disclosed by the invention, basically no residue of mucus layers exists. The method has the advantages of high efficiency, stability, good reproducibility and the like, can extract the mucus layers to the greatest degree and realize more accurate analysis of the mucus layers, and promotes the study on the formation mechanism of mucus layers; and in the chemical industry, the method can shorten the extraction time and reduce the cost.

The invention discloses a preparation technology of nano-micelles for conveying anti-tumor medicines through oral administration, namely a preparation method of nano-micelles with mucous layer permeation and P-gp inhibition dual effects. Chitosan, quercetin and 6-phosphogluconic acid are used as raw materials to prepare an amphiphilic chitosan-quercetin succinate-6-phosphogluconic acid copolymer through a condensation and esterification method and a target product is synthesized through a self-assembling technology; the nano-micelles have a good mucous layer permeation capability and also has the P-gp inhibition effect; the oral administration conveying efficiency of the anti-tumor medicines can be effectively improved. The nano-micelles can be used for medical biological materials and medicine carriers and have good research and development application prospects.

The invention belongs to the technical field of medicine, and relates to the application of a class of maleimide prodrugs targeting mucin in promoting bioadhesion and improving oral drug absorption. The structural formula of the maleimide type prodrug is as shown in (I): wherein, n=2~8; X is O, N; The prodrug compound has high drug loading, good stability, safety and available for oral administration. The maleimide group it carries can specifically bind to the mucin in the mucus layer in the gastrointestinal tract to form a mucin-prodrug complex, prolong the residence time of the drug in the gastrointestinal tract, and improve the adsorption-absorption Concentration gradients across sites facilitate passive diffusion, thereby enhancing oral absorption. The invention is a novel maleimide type prodrug with bioadhesive effect, which is used to improve the oral absorption of drugs.

The invention discloses an inhalable effervescent powder mist and its application in the preparation of medicines for treating infectious pneumonia, belonging to the technical field of medicine. The inhalable effervescent powder mist comprises active agent and effervescent agent, and the mass ratio of active agent and effervescent agent is 1:1~50; Described effervescent agent is made up of acid and alkali, and described acid comprises at least Diketopiperazine can optionally include one or more of citric acid, malic acid, fumaric acid, maleic acid, succinic acid or tartaric acid, and the base is selected from sodium carbonate, potassium carbonate, sodium bicarbonate or One or more of potassium bicarbonate. The effervescent powder mist of the present invention can provide a driving force for the active agent, that is, the drug powder, to accelerate the dissolution of the drug in the mucus layer on the surface of the bronchi and alveoli, and avoid macrophages from engulfing and clearing the drug.

The present invention relates to nanomicelles comprising a complex of a poly gamma-glutamic acid of which a part of the carboxylic group is substituted by an amine group and an oleophilic compound and, more specifically, to nanomicelles comprising a complex of a poly gamma-glutamic acid of which a part of the carboxylic group is substituted by an amine group and an oleophilic compound, a method for producing the same, and a drug delivery system using mucus layer-adhesive properties of the nanomicelles. According to the present invention, when the nanomicelles drug delivery system on the basis of the poly gamma-glutamic acid, which is a biogenous natural polymer, is utilized in the field of drug delivery to a mucus layer region, the nanomicelles drug delivery system can improve biostability and effectiveness of a drug.